MacroGenics, Inc. is developing immunotherapeutics, including monoclonal antibodies, to treat patients with cancer, autoimmune disorders, allergy, or infectious diseases.
Anti-CD3 (teplizumab)
Anti-CD32B
Anti-CD16
Capabilities